



Neuropsychiatric Lupus in clinical practice
Lúpus neuropsiquiátrico na prática clínica
Helena Alessi1, Lívia Almeida Dutra1, Pedro Braga-Neto2,3, José Luiz Pedroso1, Fabio F. Toso1, Cristiane 
Kayser4, Orlando G. P.  Barsottini1
Systemic lupus erythematosus (SLE) is a chronic auto-
immune disease involving multiple organs, characterized 
by the production of autoantibodies and the development 
of tissue injury1. The etiology of SLE is partially known 
and involves multiple genetic and environmental factors. 
Systemic lupus erythematosus more often affects non-
White women of reproductive age and more severe forms 
are seen in people of African descent, Asians, Hispanics, 
and Indians1. 
The pathogenesis of SLE is characterized by immune 
abnormalities including T-cell and B-cell hyperactivity, 
abnormal number and function of regulatory T cells, and 
immune complex deposition in various tissues. A charac-
teristic feature of SLE is the production of autoantibodies 
against double-stranded DNA, histones and nucleosomes, 
and other chromatin components. In addition, immune com-
plex and apoptotic cell removal is impaired1. These abnor-
malities could lead to the extracellular presence of chroma-
tin triggering immune cells and activation of the innate and 
adaptive immune system2.
As many as 50% of patients with SLE have neuro-
logical involvement during the course of their disease3. 
Approximately 40% of neuropsychiatric SLE (NPSLE) cases 
are a consequence of the disease itself; other causes of 
NPSLE are infections, metabolic disorders, and side effects 
of drugs4. We review the major NPSLE manifestations and 
discuss their clinical features, radiological findings, and 
treatment options.
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ABSTRACT
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease involving multiple organs, characterized by the production of 
autoantibodies and the development of tissue injury. The etiology of SLE is partially known, involving multiple genetic and environmental 
factors. As many as 50% of patients with SLE have neurological involvement during the course of their disease. Neurological manifestations 
are associated with impaired quality of life, and high morbidity and mortality rates. Nineteen neuropsychiatric syndromes have been 
identified associated with SLE, and can be divided into central and peripheral manifestations. This article reviews major neuropsychiatric 
manifestations in patients with SLE and discusses their clinical features, radiological findings and treatment options.
Keywords: systemic lupus erythematosus; lupus vasculitis, central nervous system; seizures; myelitis; autoimmune diseases.
RESUMO
Lúpus eritematoso sistêmico (LES) é uma doença autoimune crônica que envolve múltiplos órgãos e sistemas, caracterizada pela produção 
de auto anticorpos e lesão tecidual. A etiologia do LES é parcialmente conhecida e envolve interação entre fatores genéticos e ambientais. Até 
50% dos pacientes com LES apresentam envolvimento neurológico no decorrer da doença. Manifestações neurológicas estão associadas 
a prejuízo na qualidade de vida e altas taxas de mortalidade e morbidade. Foram identificadas 19 síndromes neuropsiquiátricas em 
pacientes com LES, divididas entre manifestações do sistema nervoso central e periférico. O objetivo deste artigo é revisar as manifestações 
neuropsiquiátricas mais importantes. Serão abordadas as características clínicas, os aspectos radiológicos e opções de tratamento dos 
eventos neuropsiquiátricos.
Palavras-chave: lúpus eritematoso sistêmico; vasculite associada ao lúpus, sistema nervoso central; convulsões; mielite; doenças autoimunes. 
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NEUROPSYCHIATRIC SYSTEMIC LUPUS 
ERYTEMATOSUS
The American College of Rheumatology identified 19 neu-
ropsychiatric syndromes in SLE patients that can be divided 
into central and peripheral nervous system manifestations5 
(Table 1). Although this classification includes syndromes with 
no clear physiopathological mechanism and is not specific for 
neuropsychiatric events caused exclusively by SLE, it helps the 
physician recognize any neurological involvement6.
NPSLE may be the first manifestation of the disease and 
its prevalence ranges from 21% to 95%5,6. Central nervous sys-
tem (CNS) syndromes are more common than peripheral and 
may be further classified into diffuse or focal manifestations7. 
Patients may present with single or multiple neuropsychiat-
ric events, which may not relate to systemic disease activity5.
Risk factors associated with NPSLE include CNS dam-
age or generalized SLE activity; previous neuropsychiatric 
events or other concurring neuropsychiatric manifestations; 
the presence of moderate to high titers of antiphospholipid 
antibodies (aPL) such as lupus anticoagulant and anticardio-
lipin, or anti-β2 glycoprotein 1 (either IgG or IgM), especially 
in cerebrovascular disease, myelopathy, cognitive dysfunc-
tion, seizures and movement disorders; and anti-ribosomal P 
protein antibodies (anti-P antibodies), that have been associ-
ated with lupus psychosis in some studies6,7,8,9.
Neurological manifestations are associated with 
impaired quality of life, and high morbidity and mortality 
rates. Notably, involvement of the lungs, kidneys and CNS 
can cause serious sequelae6. Since there are no biomarkers of 
CNS activity, the diagnosis of NPSLE is often made by ruling 
out secondary NPSLE. Potential pathogenic mechanisms in 
primary NPSLE are direct action of intrathecal inflammatory 
cytokines, blood-brain barrier (BBB) disruption, accelerated 
atherosclerosis and thrombotic vasculopathy caused by aPL 
antibodies4. Autoantibodies may also bind to neurons lead-
ing to neuronal dysfunction and apoptosis7,10 (Table 2). 
Headache
Headache is a common, non-specific symptom for SLE or 
other rheumatic diseases. Although tension-type headache is 
the most frequent primary headache syndrome in the general 
population, there are reports of higher prevalence of migraine 
in SLE when compared to controls11,12. Nonetheless, a recent 
meta-analysis did not confirm this finding11. Headache in 
SLE is not associated with a higher frequency of magnetic 
resonance imaging (MRI) lesions, disease activity, and bio-
markers such as aPL, anti-P, and glutamate receptor antibod-
ies (anti-NR2)12,13.
Focal neurological signs, fever or concomitant infection, 
presence of antiphospholipid syndrome (APS), immunosup-
pression, use of anticoagulants, altered mental status, menin-
gismus and generalized SLE activity are indicative of second-
ary causes of headache and require further investigation with 
brain imaging and cerebrospinal (CSF) analysis8,14. It is impor-
tant to rule out meningitis, cerebral venous sinus thrombo-
sis (mostly in patients with aPL) and cerebral or subarach-
noid hemorrhage8. In addition, secondary headaches may be 
caused by posterior reversible encephalopathy syndrome14.
Non-steroidal anti-inflammatory drugs and triptans 
can be used for pain relief. Migraine prevention therapy are 
β-blockers, anticonvulsants such as valproic acid and topira-
mate, and antidepressants15.























NPSLE: Neuropsychiatric systemic lupus erythematosus.
Table 2. Know autoantibodies association with NPSLE.
Autoantibodies Syndromes Source
LA CVD, CD, seizures Sciascia, 2014
aCL CVD, CD, seizures  and eplepsy Sciascia, 2014
aβGPI Angina and arterial or venous thrombosis Sciascia, 2014
Anti-Sm ACS Hirohata, 2014
Anti-P Psycosis Bonfa, 1987; Sciascia, 2014
Anti-NMDA CD Faust, 2010
Anti-NR2 CD Lauvsnes, 2014
AQP4 NMO Bertsias, 2010
NPSLE: Neuropsychiatric systemic lupus erythematosus; LA: Lupus anticoagulant; 
CVD: Cerebrovascular disease; CD: Cognitive dysfunction; aCL: anticardiolipin; 
ACS: Acute confusional state; AQP4: Aquaporin 4; NMO: Neuromyelitis optica.
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Cognitive dysfunction
Cognitive dysfunction (CD) is defined as a cognitive 
decline from a previous level of mental functioning docu-
mented by neuropsychological assessments adapted to the 
target population5,16. The main cognitive domains found to 
be compromised in SLE are attention, processing speed and 
memory5,16. The American College of Rheumatology recom-
mends a one-hour neuropsychological battery for CD evalu-
ation in SLE patients. It assesses simple and complex atten-
tion, verbal and visual memory, visual spatial processing, 
language (verbal fluency), reasoning/problem solving, psy-
chomotor speed and executive function (Table 3). 
Cognitive decline is defined by scores that fall between 
1.5 and 1.9 standard deviations below the mean in one or more 
cognitive domains. Cognitive impairment is defined by scores 
that fall 2.0 standard deviations below the mean16. Cognitive 
dysfunction is defined as focal if impairment exists on mea-
sures within one domain, or multifocal if impairment exists on 
measures spanning two or more domains16. Screening tests, 
i.e. Mini Mental State Examination, are non-specific and have 
low diagnostic sensitivity for CD5. Despite that, the Montreal 
Cognitive Assessment is an appropriate screening tool for 
CD because it features a frontal subcortical profile of cogni-
tive impairment in SLE. In American patients with SLE, the 
Montreal Cognitive Assessment tool had a sensitivity of 83% 
and specificity of 73% for CD using a cutoff score of 2617.
Cognitive dysfunction in SLE is associated with aPL 
antibodies, steroid use, diabetes and low level of education. 
Although depressive symptoms may reduce cognitive func-
tion, CD is not fully explained by depression18. In a compar-
ison of neuropsychological scores between patients with 
depression and those with depression and SLE, the latter 
showed even lower scores18.
Cerebral atrophy, white matter lesions and cerebral infarc-
tion have been correlated with the severity of CD8 (Figure 1). 
An apparently normal MRI in CD may be associated with micro-
structural and metabolic changes in white matter tissue suggest-
ing potentially immune-mediated myelinopathy, which is best 
seen by spectroscopy and other advanced MRI techniques19. 
The pathophysiology of CD remains to be fully understood and 
may involve vascular abnormalities, intrathecal inflammatory 
cytokines and BBB disruption. Autoantibodies might also con-
tribute to the pathogenesis of CD in SLE7. Systemic lupus ery-
thematosus patients with lupus anticoagulant are three times 
more likely to have impaired neuropsychological functioning, 
with working memory dysfunction, probably due to white mat-
ter changes and microvascular thrombosis20. Murine models 
have shown that anti-NMDA antibodies elicit neuronal death 
producing CD and emotional disturbance21. A recent study 
has shown higher levels of anti-NR2 antibodies in the CSF and 
reduced hippocampal gray matter in SLE patients when com-
pared with controls22.
Table 3. Proposed neuropsychological battery for SLE.
Tests Domains
North American Adult Reading Test Premorbid IQ
Digit Symbol Test Processing Speed
Trail Making Test Attention
Stroop Color Test Complex Attention
California Verbal Learning Test Verbal Memory
Rey Complex Figure Visual Memory
Letter Number Sequencing Working Memory
Controlled Oral Word Association Test Phonemic Verbal Fluency
Animal Naming Semantic Verbal Fluency
Finger Tapping Motor Speed
SLE: systemic lupus erythematosus.
A B C
Figure 1. Cortical atrophy in SLE. A 32-year-old female with SLE had a prior stroke due to SLE vasculitis. After four years, she 
developed mononeuritis multiplex and cognitive impairment. She was negative for aPL antibodies. (A) Brain MRI T1 sequence. 
Observe the Sylvian fissure. (B, C) Global cortical atrophy.
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The treatment for CD remains uncertain. Identification 
and management of secondary or exacerbating causes of 
CD is recommended19. Patients may respond to methylphe-
nidate or prednisone (0.5 mg/kg)19. Aspirin is only indicated 
for patients with cardiovascular comorbidities to improve 
cognitive performance; and memantine, an NMDA-receptor 
antagonist, prevents cognitive impairment from anti-NR2 
antibodies in the murine model, but it has not been effective 
in SLE patients23. Cognitive rehabilitation and psychoeduca-
tion are complementary treatments that can help improve 
subjective and objective cognitive complaints8.
Seizures
Epilepsy occurs in 12% to 22% of patients with SLE and 
is associated with increased morbidity and mortality8. A sin-
gle isolated seizure is more frequently seen and a generalized 
tonic-clonic seizure is the most common type (67% to 88%), 
but a simple partial and complex seizure can also occur8. 
Abnormalities on the EEG are common (60% to 70%) in SLE, 
and epileptiform EEG patterns suggest the seizure is likely to 
recur (73% positive predictive value, 79% negative predictive 
value)24. Patients with seizures show more gray matter hyper-
intensities on MRI images and may develop brain atrophy13.
Inflammatory processes are believed to play a major role 
in the pathogenesis of epileptic seizures25. Ischemic vascular 
disease and antibodies that bind to cerebral tissues such as 
anticardiolipin and anti-Sm have been associated with sei-
zures24. Epilepsy in SLE has also been associated with APS, 
disease activity, multiple NPSLE manifestations (i.e., psycho-
sis, stroke), and severe baseline organ damage24,26. Although 
seizure is classified as a diffuse CNS manifestation, it may 
develop in focal and inflammatory NPSLE. For that reason, 
the evaluation of patients with seizures should include brain 
imaging and CSF analysis to rule out infections, vasculitis, 
and mechanisms suggestive of focal NPSLE. 
Posterior reversible encephalopathy syndrome is a clini-
cal-radiological syndrome characterized by seizures, altered 
mental status, and visual impairment27. It is an uncommon 
condition with a good prognosis, usually reversible and rarely 
recurrent14. An MRI in this syndrome shows bilateral asym-
metrical isointensities or hypointensities in T1, hyperintensi-
ties in T2 and fluid-attenuated inversion recovery sequences 
in the parietal-temporal-occipital regions27. Approximately 
50% of patients require treatment with both anticonvulsants 
and antihypertensive drugs27. 
Long-term anticonvulsants are recommended for patients 
with recurrent seizures or risk of recurrence (i.e., recurrent sei-
zures in 24 hours, EEG abnormalities, prior brain injury with 
structural abnormalities in brain MRI)8. Immunosuppressive 
therapy is indicated for those with systemic disease activity. 
Acute confusional state
Acute confusional state is a disturbance in conscious-
ness or alertness, and subsequent attentional deficits that 
are accompanied by cognitive decline and/or affect or mood 
changes. It has been associated with the presence of anti-NR2 
antibodies and anti-Sm antibodies in the CSF10,28. The patho-
genic mechanism behind this diffuse neuropsychiatric mani-
festation seems to be primarily inflammatory with increased 
production of inflammatory mediators, BBB disruption, 
and intrathecal immune complex formation6. Risperidone 
(2 mg/day) may be a therapeutic option for an acute confu-
sional state29. Yet, corticosteroids and immunosuppression 
should be considered depending on the patient’s condition8.
Psychosis, depression and anxiety 
A systematic review found a prevalence of 17% to 75% of 
depressive disorders among patients with SLE30. Mood dis-
orders were associated with disease activity, high predni-
sone doses (≥ 20 mg), cutaneous disease, and longitudinal 
extensive transverse myelitis31. Adverse drug events may also 
contribute to the occurrence or exacerbation of depressive 
symptoms in some patients32. There is no evidence on the 
use of neuroimaging or serological markers for diagnosing 
mood and anxiety disorders, although anti-P and anti-NMDA 
receptor autoantibodies have been associated with a higher 
incidence of depression in patients with SLE8,32. Serum lev-
els of tumor necrosis factor alpha are also increased in SLE 
patients with mood and anxiety disorders suggesting the role 
of inflammation in depression31.
Anti-P antibodies have been specifically associated with 
psychosis in patients with SLE, although some studies have 
failed to verify this association7,9. High levels of anti-P anti-
bodies found in serum samples of SLE patients with psycho-
sis were compared to those of SLE patients with other neuro-
psychiatric manifestations, patients with non-SLE psychosis, 
and controls. Anti-P antibody levels were 5- to 30-fold higher 
during the active phase of SLE psychosis, but not during other 
SLE manifestations9. In fact, several in vivo and in vitro studies 
have shown that anti-P antibodies can bind to neuronal anti-
gens, penetrate neuronal cells, and inhibit protein synthesis in 
neuronal cells including in hippocampal neurons. Moreover, 
a recent study has shown that anti-P antibodies interact with 
neuronal antigens leading to neuronal apoptosis32.
Both psychosis and major depressive disorders due to SLE 
are rare, while steroid-induced psychosis is an uncommon 
side effect. Glucocorticoids and immunosuppressive therapy 
may be considered for psychosis associated with SLE, espe-
cially in the presence of generalized disease activity8.
Cerebrovascular disease
Cerebrovascular events account for 10% to 15% of deaths 
in SLE patients33. Ischemic stroke (IS) is the most com-
mon condition. Patients with SLE have a twofold increase 
in the risk of IS, a threefold increase in the risk of intrace-
rebral stroke, and a fourfold increase in the risk of sub-
arachnoid hemorrhage compared to the general popula-
tion33. Intracerebral and subarachnoid hemorrhages are 
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infrequent in SLE patients, and affect mostly young individu-
als. They usually occur in the first year following the diagno-
sis, and result in high mortality and long-term morbidity33.
Systemic lupus erythematosus disease severity, 
hypertension and hyperlipidemia were independent pre-
dictors of stroke and stroke severity in a follow-up study34. 
However, traditional risk factors do not fully explain the 
high prevalence of IS in patients with SLE. Accelerated 
atherosclerosis, and inflammatory mediators such as 
complement components, cytokines and aPL antibodies 
may also play a role in the development of cerebrovascu-
lar disease4. It is noteworthy that high cumulative doses of 
steroids could also be a risk factor for accelerated athero-
sclerosis, leading to increased risk of stroke33. Vasculitis is 
a rare cause of stroke in SLE, accounting for 7% of cases in 
some case series.
Patients with SLE and stroke should be routinely screened 
for APS, which is characterized by the presence of aPL anti-
bodies, (arterial or venous) vascular thrombosis and preg-
nancy complications including eclampsia or pre-eclampsia 
and miscarriage35 (Figure 2). Stroke in APS is either throm-
botic or embolic35. Patients with SLE and APS may also pres-
ent with renal involvement and valvulopathy due to immune 
complex deposition. One-third or more of APS strokes are 
due to embolism associated with cardiac valve vegetations, 
and some patients may have sterile endocarditis35.
A recent systematic review pointed to a fivefold increase 
in the risk of IS or transient ischemic attack in patients with 
aPL antibodies compared to controls36. The RATIO (Risk 
of Arterial Thrombosis in Relation to Oral Contraceptives) 
study showed that lupus anticoagulant is a major risk factor 
for IS, particularly in young women. Anti-β2-glycoprotein is 
also associated with higher IS risk37. Lupus anticoagulant is 
a stronger predictor of thrombosis compared to anticardio-
lipin and usually involves large and small vessels.
Modifiable risk factors should be focused upon as part of 
primary and secondary IS prevention strategies for patients 
with SLE38. Long-term oral anticoagulant is recommended 
for patients with APS and SLE, to prevent recurrence of both 
arterial and venous thrombosis, and also for patients with a 
high-risk cardioembolic source. Glucocorticoids and immu-
nosuppressive therapies do not reduce the risk of IS38.
Movement disorders
Movement disorders are uncommon neuropsychiatric 
manifestations in SLE. Nonetheless, parkinsonism, myoc-
lonus and dystonia were described and an autoimmune or 
thromboembolic disease mechanism has been proposed 
for their occurrence39. Chorea is the most described mani-
festation and may be the first manifestation in SLE occur-
ring in 2% of adult patients, predominantly in women. It 
can be unilateral or bilateral and remit spontaneously. 
Current evidence suggests an autoimmune mechanism 
related to aPL antibodies, but focal cerebral ischemia is 
rarely evidenced39.
Sydenham chorea is the most common cause of acute 
chorea in children and it is one important differential diag-
nosis in chorea associated with lupus, especially in pediat-
ric patients. Sydenham chorea is an autoimmune disorder 
and most cases develop following a rheumatic fever or strep-
tococcal infection40. Sydenham chorea and lupus may have 
similar findings in brain single-photon emission computed 
tomography. Both diseases showed hyperconcentration of 
the radiotracer in the basal ganglia, possibly due to changes 
in the basal ganglia microcirculation or to a BBB abnormality 
secondary to the inflammatory process41.
A B
Figure 2. Large vessel thrombosis in antiphospholipid syndrome. (A) Digital arteriography showing normal left carotid artery. (B) 
Right carotid thrombosis in an SLE patient with stroke and positive lupus anticoagulant antibodies.
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Parkinsonism may occur in children or adult patients. 
Dopaminergic drugs as well as immunomodulatory ther-
apy may improve their symptoms. Antiphospholipid syn-
drome-related parkinsonism is associated with vasculop-
athy, poor response to levodopa and cerebral infarction. 
Systemic lupus erythematosus patients with APS may also 
present with tremor, tics, myoclonus and corticobasal 
degeneration-like syndrome42.
Focal dystonia including torticollis and blepharospasm have 
also been reported. They may respond to immunomodulatory 
therapies. Some patients with SLE may have complex move-
ment disorders including an association of hypokinetic and 
hyperkinetic manifestations that are frequently associated with 
other neuropsychiatric symptoms42. 
Aseptic meningitis
The incidence of aseptic meningitis in SLE patients has 
been estimated at 1.4% to 1.6% in retrospective studies. 
It can occur at any time during the disease course, usually 
during flares32,43. Because patients are often receiving immu-
nosuppressant agents, bacterial, viral, fungal and tubercu-
losis infection must be ruled out43. Clinical features of asep-
tic meningitis include headache and altered mental status. 
Cerebrospinal fluid analysis may reveal lymphocytic cells 
and protein. Although spontaneous remission may occur, 
most cases are effectively treated with glucocorticoids and 
immunosuppressive therapy8.
Myelopathy 
Lupus myelitis occurs in 1% to 1.5% of cases44. It mani-
fests as transverse myelitis or asymmetrical spinal cord syn-
drome with hemiparesis, tetraparesis, bladder involvement, 
neuropathic pain, and presence of a sensory level. Acute 
transverse myelitis is the first clinical manifestation in nearly 
half of the patients with SLE and it usually occurs within the 
first five years after diagnosis44. Underlying pathophysiologi-
cal mechanisms are not yet known. Histopathology findings 
have revealed ischemic/thrombotic myelopathy (especially 
in acute cases) or localized acute inflammation44.
Systemic lupus erythematosus myelitis has two distinct 
clinical patterns: gray-matter and white-matter myelitis. 
Patients with gray-matter myelitis often have a prodromal 
phase of fever and urinary retention at onset that rapidly 
evolves to paraplegia during disease activity. An MRI reveals 
spinal cord swelling and enhancement45. White-matter 
myelitis has been associated with a less severe presentation 
and slower progression, characterized by upper motor neu-
ron spasticity and hyperreflexia45.
The CSF analysis may show mild pleiocytosis exceed-
ing 10 cells/mm3, but polymorphonuclear predominance 
has also been reported. There is often an elevation of IgG 
in CSF44. An MRI may show increased signal and longitudi-
nal extensive transverse myelitis involving at least three ver-
tebral segments has been observed in 91.7% of gray-matter 
myelitis45. There may be no MRI abnormalities in some cases. 
Approximately 30% of patients may have brain involvement, 
and therefore it is advisable to perform brain MRI44.
There may also be a co-occurence of SLE with neuromyeli-
tis optica (NMO). So patients should be tested for NMO-IgG 
anti-aquaporin 4 (AQP4) antibodies8. Neuromyelitis optica-
IgG is positive in 10% of SLE cases with myelitis and approxi-
mately 20% of patients may fulfill clinical criteria for NMO as 
reported in some series. Because myelitis in SLE may respond 
to cyclophosphamide whereas patients with NMO tend to 
have a worse outcome, it is important to test patients at the 
first manifestation of the disease before immunosuppression 
and to repeat it during the disease course (Figure 3). 
In the presence of myelitis, overlap of APS, Sjögren’s syn-
drome, and NMO should be investigated32. The prevalence of 
aPL ranges from 18% to 60% in SLE patients with myelitis. 
Spinal cord necrosis secondary to thrombosis has been pro-
posed as an etiological factor for transverse myelitis in SLE32.
Treatment involves therapy with high-dose steroids fol-
lowed by intravenous cyclophosphamide. The addition of 
plasmapheresis to a regimen of intravenous cyclophospha-
mide and steroids led to higher remission rates32. Relapse 
of lupus-associated acute transverse myelitis is common 
(50–60%) during steroid tapering. Severity of neurologi-
cal impairment (muscle strength < 3/5) is the most impor-
tant prognostic variable46. Other prognostic variables in 
SLE-associated myelitis are urinary catheter use at the neu-
rological nadir and no cyclophosphamide therapy. Only a 
small proportion of patients fully recover.
Peripheral nervous system involvement
Some SLE patients may present with variable periph-
eral nervous system involvement (2–3%)5 (Table 1). Clinical 
symptoms include combined paresthesia, pain, autonomic 
dysfunction, peripheral ataxia, weakness, and atrophy. 
Peripheral neuropathy is most often seen in older patients at 
diagnosis, and those with CNS manifestations and active sys-
temic disease. Differences in disease activity may account for 
variation in the frequency and spectrum of peripheral neu-
ropathies in different cohorts47,48. Electroneuromyography 
can help identify neurophysiological patterns. Analysis of the 
CSF is useful in inflammatory demyelinating polyradiculo-
neuropathy. Nerve biopsy is rarely useful in such patients8. 
Mild distal symmetric axonal sensory or sensorimo-
tor neuropathy is the most common subtype of peripheral 
involvement, whereas mononeuropathies are the second 
most common presentation. Patients may present with 
sudden weakness requiring aggressive immunosuppressive 
therapy. Although small-fiber neuropathy is not included in 
the American College of Rheumatology definitions, Oomatia 
reported a prevalence of 17.1% in SLE patients with periph-
eral involvement5,49. Electrodiagnostic studies are usually 
normal and a skin biopsy demonstrates loss of intraepider-
mal nerve fibers. There are two distinct clinicopathologic 
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entities: length-dependent, small-fiber neuropathy with a 
stocking-and-glove distribution and abnormal skin biopsy 
findings restricted to the distal leg and non-length-depen-
dent, small-fiber neuropathy with an unorthodox pattern 
of patchy, asymmetric, and proximal neuropathic pain that 
can affect the face, torso, and proximal extremities50.
Mononeuritis multiplex is found in 33% of SLE patients 
with peripheral involvement, usually with sudden weakness 
in different nerve territories51,52. It can occur at any time dur-
ing disease course, either at the onset of SLE or later dur-
ing its evolution51,52. In most cases, the onset was dramatic 
with sudden weakness in different nerve territories. These 
patients, in general, had substantially higher disease activity, 
showed more severe deficits and often required more aggres-
sive immunosuppressive therapy.
Chronic inflammatory demyelinating polyneuropathy 
and acute inflammatory demyelinating polyneuropathy 
are severe. Forms of chronic inflammatory demyelinating 
polyneuropathy can present before or at the onset of another 
clinical manifestations of SLE53. Acute inflammatory demy-
elinating polyneuropathy, an ascending motor radiculoneu-
ropathy that resembles Guillain-Barré syndrome clinically 
and electrodiagnostically, is a relatively rare condition, affect-
ing up to 1% of the lupus patients54.
Symptomatic therapy alone may be considered for mild 
peripheral neuropathy, especially when there is no motor 
impairment32. Glucocorticoids alone or together with immu-
nosuppressive therapy have been used with good outcomes 
(60–75% response rate). Intravenous immunoglobulin, 
plasma exchange, and rituximab have been used in severe 
and refractory cases8. 
Cranial neuropathies
Cranial neuropathies may involve the eighth nerve, the 
oculomotor nerve (third, fourth and sixth), and less com-
monly the fifth and the seventh nerves8. Cranial neuropathies 
A B C
D FE
Figure 3. Myelitis in SLE. (A, B, C)  Brain MRI fluid-attenuated inversion recovery sequence. Arrows: extensive myelitis extending to 
the area postrema in the dorsal medulla. (D) Axial T2 sequence showing spinal cord involvement in the dorsal region. (E) Sagittal 
T2 sequence. Arrows: Observe the multiple lesions, one involving more than three spinal segments. (F) Sagittal T1 sequence: pial 
contrast enhancement. Patient with SLE and APS negative for AQP4, had an isolate demyelinating episode, was treated with 
plasmapheresis, cyclophosphamide and steroids with complete recovery. 
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have been reported in 5–42%, rarely as an isolated manifesta-
tion55. When the oculomotor, trochlear and abducent nerves 
are involved, myasthenia gravis should be ruled out. Different 
mechanisms have been proposed such as vasculitis second-
ary to SLE, microinfarction of the capillaries or arterioles in 
the temporal bone, and thrombosis in the otologic region56. 
Autoimmune sensory neural hearing loss in SLE is associ-
ated with a poor prognosis.
Optic neuropathy is infrequent (< 1%) and can manifest 
as optic neuritis and ischemic/thrombotic optic neuropathy, 
which is usually unilateral and related to aPL57. Only 50% of 
patients with SLE-associated optic neuritis recovered com-
plete visual acuity (visual acuity better than 20/25)58. Bilateral 
or chiasm involvement, severe pain accentuated by ocular 
movements and profound visual impairment are character-
istic of SLE-associated optic neuritis. The differential diagno-
sis includes NMO and multiple sclerosis. 
More recently, studies with small samples reported a fre-
quency of audiovestibular symptoms between 25% and 67% 
in SLE patients59,60. Such manifestations include sensorineu-
ral hearing loss, often accompanied by vertigo and tinnitus 
and other symptoms compatible with Menière’s disease60. 
Autoimmune sensory neural hearing loss in SLE is associ-
ated with a poor prognosis.
Patients with SLE may present with asymptomatic cranial 
neuropathies, and the eighth nerve is the most commonly 
affected, followed by the seventh, the second, and the fifth 
nerves. Anti-ribosomal P protein and anti-DNA antibodies 
are associated with such subclinical manifestation55.
In conclusion, NSLE exhibits variable clinical manifes-
tations and a heterogeneous disease course and prognosis. 
Since there are no biomarkers for CNS involvement and dis-
ease activity, diagnosis should be based on clinical features 
as well as imaging and laboratory findings. Central nervous 
system infections, metabolic abnormalities, valvular heart 
disease, and adverse drug effects should be ruled out. All 
patients with NPSLE should be routinely screened for APS, 
since overlap may occur even in non-ischemic manifestation.
For therapeutic purposes, the most important decision is 
to classify primary NPSLE into either ischemic or inflamma-
tory phenotypes and treatment should be individualized61. 
Severe inflammatory phenotypes should receive immuno-
suppressant and/or steroid therapy, whereas ischemic phe-
notypes should receive aspirin or anticoagulation. In mild 
cases, therapy consists of antidepressants, anticonvulsants, 
or antipsychotics only. 
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